(RTTNews) - Vitaris Inc. (VTRS), a healthcare company, announced financial results of the third quarter on Thursday, noting a wider net loss owing to higher income tax provisions and litigation costs.

Vitaris' Q3 Loss Expands To $325 Mln Despite Consistent Sales; 2026 Guidance Raised 

Viatris Inc. reported its third-quarter 2026 financial results, delivering total revenues of $3.75 billion, which were essentially flat compared to the third quarter of 2025. The company recorded a U.S. GAAP net loss of $325 million, compared to a U.S. GAAP net loss of $128 milli

Viatris Inc. Reports Third-Quarter 2026 Total Revenues of $3.75 Billion and Raises Full-Year Guidance

(RTTNews) - Below are the earnings highlights for Viatris Inc. (VTRS):

Viatris Inc. Q3 Earnings Summary 

(RTTNews) - Viatris Inc. (VTRS) announced that its wholly owned subsidiary, Peach Purchaser Sub Inc., has commenced a tender offer to acquire all outstanding shares of Pacira BioSciences, Inc. (PCRX) for $36.50 per share in cash.

Viatris Begins Cash Tender Offer To Acquire Pacira At $36.50 Per Share; Stock Down 

(RTTNews) - Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.

Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win 

(RTTNews) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.

FDA Approves Viatris' RYZUMVI For Presbyopia Treatment 

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc. News